MOUNTAIN VIEW, Calif., May 1, 2013 (GLOBE NEWSWIRE) -- A new comprehensive treatment algorithm for diabetes from the American Association of Clinical Endocrinologists (AACE) is the first to recommend active obesity management, which includes lifestyle modification and, if appropriate, the use of FDA-approved anti-obesity medications, as first-line therapy in the management of chronic cardiometabolic diseases, including prediabetes, diabetes, dyslipidemia and hypertension.
"As a respected and influential institution in the field of endocrinology, it is encouraging to see the AACE has addressed the critical role of effective medical obesity treatments in the management of chronic cardiometabolic disease," said Peter Tam, president of VIVUS, Inc. (Nasdaq:VVUS) "Endocrinologists are the thought leaders in weight management and metabolic diseases, and we believe that healthcare providers, including primary care physicians, along with payors and public policy makers, will recognize the significance of these new guidelines."
The AACE Comprehensive Diabetes Management Algorithm 2013 will be presented and discussed during the AACE 22nd Annual Scientific and Clinical Congress, May 1 – 5, 2013 in Phoenix, AZ. The guidelines are available online and in the March/April 2013 issue of Endocrine Practice.About Qsymia Qsymia ® (phentermine and topiramate extended-release) capsules CIV is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts